SCHEMBL4843937

SCHEMBL4843937

Nc1ccc(O)c(F)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 3/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
EP300 Q09472 2/20 0.38
KAT2B Q92831 2/20 0.38
KAT8 Q9H7Z6 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
HDAC3 O15379 1/20 0.38
IDO1 P14902 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
CYP3A4 P08684 3/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CSNK2A3 Q8NEV1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854156 0.84 HSD17B10 (0.40) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL4847774 0.81 ALOX15 (0.43) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL1456970 0.77 CYP3A4 (0.55) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL572491 0.77 EP300 (0.42) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL30968537 0.75 CYP3A4 (0.40) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL29782293 0.75 CYP3A4 (0.59) ALOX15ALDH1A1HSD17B10MAPK1HPGD
SCHEMBL911858 0.75 CYP3A4 (0.59) ALOX15ALDH1A1HSD17B10MAPK1HPGD
SCHEMBL14908341 0.75 EP300 (0.41) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
SCHEMBL16555577 0.75 CYP3A4 (0.40) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2
Hydrochloric Acid SCHEMBL29972242 0.75 CYP3A4 (0.52) ALOX15ALDH1A1HSD17B10MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115754028-A Method for separating and detecting aniline impurities in fluvastatin 重庆医药工业研究院有限责任公司 2023-03-07 CN claimed
CN-114621106-A Preparation method of tyrosine kinase drug intermediate 重庆医药工业研究院有限责任公司 2022-06-14 CN claimed
US-20050143425-A1 Preparation of halogenated 4-aminophenols LANXESS DEUTSCHLAND GMBH (DE) 2005-06-30 US claimed
CN-1616412-A Process for the preparation of halogen containing 4-amino phenols BAYER CHEMICALS AG (DE) 2005-05-18 CN claimed
EP-1514865-A1 Process for the preparation of halogen containing 4-amino phenols Bayer Chemicals AG (DE) 2005-03-16 EP claimed
CN-115754028-A Method for separating and detecting aniline impurities in fluvastatin 重庆医药工业研究院有限责任公司 2023-03-07 CN disclosed
CN-115754028-A Method for separating and detecting aniline impurities in fluvastatin 重庆医药工业研究院有限责任公司 2023-03-07 CN disclosed
CN-114149449-B Alkynyl-coupled difluorophenyl pyridone HIV integrase inhibitor, preparation method and application 吉斯凯(苏州)制药有限公司 2023-01-03 CN disclosed
EP-3689351-B1 QUINOLINE DERIVATIVE AND APPLICATION THEREOF AS TYROSINE KINASE INHIBITOR CHONGQING PHARMACEUTICAL INDUSTRIAL RES INSTITUTE CO LTD (CN) 2022-11-02 EP disclosed
CN-114621106-A Preparation method of tyrosine kinase drug intermediate 重庆医药工业研究院有限责任公司 2022-06-14 CN disclosed
CN-114621106-A Preparation method of tyrosine kinase drug intermediate 重庆医药工业研究院有限责任公司 2022-06-14 CN disclosed
US-20220175756-A1 APPLICATION OF COMBINATION OF QUINOLINE DERIVATIVE AND IMMUNOMODULATOR IN PREPARATION OF ANTITUMOR DRUGS CHONGQING PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE CO., LTD. (CN) 2022-06-09 US disclosed
US-20200262791-A1 QUINOLINE DERIVATIVE AND USE THEREOF AS TYROSINE KINASE INHIBITOR Chongqing Pharmaceutical Industrial Research Institute Co. Ltd. (CN) 2020-08-20 US disclosed
EP-3689351-A1 QUINOLINE DERIVATIVE AND APPLICATION THEREOF AS TYROSINE KINASE INHIBITOR Medshine Discovery Inc. (CN) 2020-08-05 EP disclosed
WO-2015057963-A1 FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed
US-20080139795-A1 Preparation of halogenated 4-aminophenols LANXESS DEUTSCHLAND GMBH (DE) 2008-06-12 US disclosed
US-7358397-B2 Preparation of halogenated 4-aminophenols LANXESS DEUTSCHLAND GMBH (DE) 2008-04-15 US disclosed
US-20050143425-A1 Preparation of halogenated 4-aminophenols LANXESS DEUTSCHLAND GMBH (DE) 2005-06-30 US disclosed
CN-1616412-A Process for the preparation of halogen containing 4-amino phenols BAYER CHEMICALS AG (DE) 2005-05-18 CN disclosed
EP-1514865-A1 Process for the preparation of halogen containing 4-amino phenols Bayer Chemicals AG (DE) 2005-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139795-A1 Preparation of halogenated 4-aminophenols CYP4X1, CYP4B1, PAH ALOX15 3542/4885ALDH1A1 569/4885HSD17B10 440/4885
US-20200262791-A1 QUINOLINE DERIVATIVE AND USE THEREOF AS TYROSINE KINASE INHIBITOR ABL1, JAK2, FLT3 ALOX15 4647/4885ALDH1A1 2450/4885HSD17B10 2595/4885
US-20050143425-A1 Preparation of halogenated 4-aminophenols CYP4X1, HPD, CYP4F8 ALOX15 3692/4885ALDH1A1 956/4885HSD17B10 541/4885
US-20220175756-A1 APPLICATION OF COMBINATION OF QUINOLINE DERIVATIVE AND IMMUNOMODULATOR IN PREPARATION OF ANTITUMOR DRUGS IFNG, IL2, MCL1 ALOX15 3761/4885ALDH1A1 1376/4885HSD17B10 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.